Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Phase 2CompletedNCT01951625

Bayer456 enrolled

Overview

Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

456

Conditions

Heart Failure

Interventions

Vericiguat (BAY1021189) (1.25 mg)DRUG

1.25 mg BAY1021189 tablets

Vericiguat (BAY1021189) (5 mg)DRUG

5 mg BAY1021189 tablets

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Worsening chronic heart failure (WCHF) requiring hospitalization (or intravenous diuretic treatment for HF without hospitalization) with initiation of study treatment after clinical stabilization * Left ventricular ejection fraction (LVEF) \<45% by echocardiography at randomization Exclusion Criteria: * Intravenous inotropes at any time after hospitalization

Locations (157)

Outcomes

Primary Outcomes

Change From Baseline in Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) to Week 12

Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) is a circulating plasma biomarker of cardiovascular function and prognosis in heart failure.

Time frame: Baseline, Week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Fountain Valley, California, United States

Unnamed facility

Wilmington, Delaware, United States

Unnamed facility

Fort Lauderdale, Florida, United States

Unnamed facility

Jacksonville, Florida, United States

Unnamed facility

Naples, Florida, United States

Unnamed facility

Atlanta, Georgia, United States

Unnamed facility

Macon, Georgia, United States

Unnamed facility

New Orleans, Louisiana, United States

Unnamed facility

Detroit, Michigan, United States

Unnamed facility

Minneapolis, Minnesota, United States

...and 147 more locations